Cover Image

Gastrointestinal toxicity of gemtuzumab ozogamicin: real-life data from the AMLCG, SAL, and CELL study groups

TO THE EDITOR:The CD33-directed antibody-drug-conjugate “gemtuzumab ozogamicin” (GO) in combination with the 7+3 standard regimen is currently approved for the treatment of CD33+ acute myeloid leukemia (AML). Although the pivotal ALFA-0701 study did not show a significantly increased toxicity using...

Full description

Saved in:
Bibliographic Details
Main Authors: Knabe, Ricarda (Author) , Muller, Philippe (Author) , Schliemann, Christoph (Author) , Hanoun, Maher (Author) , Unglaub, Julia Marie (Author) , Weinbergerová, Barbora (Author) , Mayer, Jiří (Author) , Krekeler, Carolin (Author) , Krause, Stefan W. (Author) , Kaufmann, Martin (Author) , Kraus, Sabrina (Author) , Steffen, Björn (Author) , Modemann, Franziska (Author) , Subklewe, Marion (Author) , Bücklein, Veit (Author) , Kunz, Wolfgang G. (Author) , Rudelius, Martina (Author) , von Bergwelt-Baildon, Michael (Author) , Gutmair, Katja (Author) , Hoster, Eva (Author) , Herold, Tobias (Author) , Röllig, Christoph (Author) , Spiekermann, Karsten (Author)
Format: Article (Journal) Editorial
Language:English
Published: July 8 2025
In: Blood advances
Year: 2025, Volume: 9, Issue: 13, Pages: 3336-3339
ISSN:2473-9537
DOI:10.1182/bloodadvances.2024014570
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1182/bloodadvances.2024014570
Get full text
Author Notes:Ricarda Knabe, Philippe Muller, Christoph Schliemann, Maher Hanoun, Julia Marie Unglaub, Barbora Weinbergerová, Jiří Mayer, Carolin Krekeler, Stefan W. Krause, Martin Kaufmann, Sabrina Kraus, Björn Steffen, Franziska Modemann, Marion Subklewe, Veit Bücklein, Wolfgang G. Kunz, Martina Rudelius, Michael von Bergwelt-Baildon, Katja Gutmair, Eva Hoster, Tobias Herold, Christoph Röllig, and Karsten Spiekermann
Description
Summary:TO THE EDITOR:The CD33-directed antibody-drug-conjugate “gemtuzumab ozogamicin” (GO) in combination with the 7+3 standard regimen is currently approved for the treatment of CD33+ acute myeloid leukemia (AML). Although the pivotal ALFA-0701 study did not show a significantly increased toxicity using 7+3 + GO compared with 7+3,1 a slightly higher rate of severe gastrointestinal (GI) toxicity was reported (16% vs 10%), and additional evidence of GO-associated GI toxicity was published.2,3 We observed several cases of severe GI toxicity and therefore analyzed patients treated with GO in a real-world setting.
Item Description:Online veröffentlicht: 30. Juni 2025
Gesehen am 26.11.2025
Physical Description:Online Resource
ISSN:2473-9537
DOI:10.1182/bloodadvances.2024014570

Similar Items